AzTrials
AzTrials

Rheumatoid ArthritisPhase 3NCT00721123

A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis

A Phase 3 study testing Tocilizumab in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 69 sites in 17 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This open-label, international multi-center extension study WA18695 was designed to assess the long term safety of tocilizumab in patients who had moderate to severe active rheumatoid arthritis (RA). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
Tocilizumab
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
538 participants
Where
69 sitesin 17 countries
Study dates
Aug 2005to May 2012
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients who have completed participation in the Phase III study WA17822 (NCT00106548) in adult rheumatoid arthritis.

Who cannot join

  • Treatment with any investigational agent since the last administration of study drug in WA17822.
  • Treatment with intravenous (IV) gammaglobulin, plasmapheresis, or Prosorba column since the last administration of study drug in WA17822.
  • Treatment with an anti-tumor necrosis factor or anti-interleukin-1 agent, or a T cell costimulation modulator since the last administration of study drug in WA17822.
  • Previous treatment with any cell-depleting therapies.
  • Parenteral, intramuscular, or intra-articular corticosteroids within 6 weeks prior to baseline.

Trial locations and contacts

69 sites in 17 countries.

69 sites in 17 countries

Canada11 sites
  • Study site

    Burlington, Ontario, L7R 1E2

  • Study site

    Calgary, Alberta, T2N 2T9

  • Study site

    Montreal, Quebec, H1T 2M4

  • Study site

    Montreal, Quebec, H2L 1S6

  • Study site

    Newmarket, Ontario, L3Y 3R7

  • Study site

    Ottawa, Ontario, K1H 1A2

  • Study site

    Sainte-Foy, Quebec, G1W 4R4

  • Study site

    St. John's, Newfoundland and Labrador, A1A 5E8

  • Study site

    Toronto, Ontario, M4N 3M5

  • Study site

    Victoria, British Columbia, V8V 3P9

  • Study site

    Winnipeg, Manitoba, R3A 1M3

Other trials in Canada

Germany7 sites
  • Study site

    Bad Bramstedt, 24576

  • Study site

    Bad Nauheim, 61231

  • Study site

    Baden-Baden, 76530

  • Study site

    Berlin, 14059

  • Study site

    Cologne, 50924

  • Study site

    Erlangen, 91056

  • Study site

    Heidelberg, 69120

Other trials in Germany

France6 sites
  • Study site

    Besançon, 25030

  • Study site

    Créteil, 94010

  • Study site

    Le Mans, 72000

  • Study site

    Paris, 75475

  • Study site

    Paris, 75571

  • Study site

    Paris, 75679

Other trials in France

Israel6 sites
  • Study site

    Beersheba, 84101

  • Study site

    Haifa, 31048

  • Study site

    Haifa, 31096

  • Study site

    Jerusalem, 91120

  • Study site

    Petah Tikva, 49100

  • Study site

    Tel Aviv, 64239

Other trials in Israel

Mexico6 sites
  • Study site

    Chihuahua City, 31000

  • Study site

    Guadalajara, 44690

  • Study site

    México, 44620

  • Study site

    Mexico City, 07760

  • Study site

    Mexico City, 14080

  • Study site

    San Luis Potosí City, 78240

Other trials in Mexico

Italy5 sites
  • Study site

    Cona (ferrara), 44124

  • Study site

    Gazzi, 98125

  • Study site

    Palermo, 90127

  • Study site

    Siena, 53100

  • Study site

    Udine, 33100

Other trials in Italy

Argentina3 sites
  • Study site

    Buenos Aires, 1405

  • Study site

    Buenos Aires, C1015ABO

  • Study site

    Buenos Aires, C1428DQG

Other trials in Argentina

Australia3 sites
  • Study site

    Adelaide, 5041

  • Study site

    Maroochydore, 4558

  • Study site

    Shenton Park, 6008

Other trials in Australia

Austria3 sites
  • Study site

    Vienna, 1090

  • Study site

    Vienna, 1130

  • Study site

    Vienna, 1160

Other trials in Austria

Bulgaria3 sites
  • Study site

    Sofia, 1606

  • Study site

    Sofia, 1784

  • Study site

    Varna, 9010

Other trials in Bulgaria

Hong Kong3 sites
  • Study site

    Hong Kong, 852

  • Study site

    Hong Kong

  • Study site

    Tuenmen, 852

Other trials in Hong Kong

Hungary3 sites
  • Study site

    Budapest, 1023

  • Study site

    Debrecen, 4032

  • Study site

    Pécs, 7632

Other trials in Hungary

Thailand3 sites
  • Study site

    Bangkok, 10400

  • Study site

    Bangkok, 10700

  • Study site

    Chiang Mai, 50200

Other trials in Thailand

Brazil2 sites
  • Study site

    Porto Alegre, 91350-200

  • Study site

    São Paulo, 04027-000

Other trials in Brazil

Singapore2 sites
  • Study site

    Singapore, 119074

  • Study site

    Singapore, 258499

Other trials in Singapore

Switzerland2 sites
  • Study site

    Bern, 3010

  • Study site

    Lausanne, 1011

Other trials in Switzerland

Slovakia1 site
  • Study site

    Piešťany, 921 01

Other trials in Slovakia

About this study

Official title: Long-term Extension Study of Safety During Treatment With Tocilizumab (MRA) in Patients Completing Treatment in WA17822

This open-label, international multi-center extension study WA18695 was designed to assess the long term safety of tocilizumab in patients who had moderate to severe active rheumatoid arthritis (RA). Patients enrolled in the WA18695 study had previously received treatment in the 24-week, placebo-controlled, Phase III Study WA17822. Eligible patients were assigned to treatment with 8 mg/kg tocilizumab every 4 weeks for a maximum of 5 years.

Read the detailed description

The primary objective of this extension study was to assess the long-term safety of 8 mg/kg tocilizumab with regard to adverse events (AEs) and laboratory result abnormalities.

The secondary objectives were as follows:

  • To explore the possibility of reducing concomitant steroid treatment
  • To determine the long-term efficacy of 8 mg/kg tocilizumab with regard to reduction in signs and symptoms
  • To better understand and predict tocilizumab efficacy, response, safety, and progression of rheumatoid arthritis (RA) and associated diseases with regard to its effect on biomarkers

No viable biomarkers for TCZ treatment effects were identified from the controlled studies. There were, therefore, no biomarkers that warranted further investigation in long-term studies, so no biomarker data are reported.

The extension study WA18695 was an open-label, international multi-center study in patients with moderate to severe active rheumatoid arthritis (RA) who had completed treatment in the 24 weeks placebo-controlled Phase III study WA17822. Patients entering WA17822 had an inadequate response to methotrexate (MTX), and, during WA17822, patients had received treatment with intravenous infusions of tocilizumab 4 mg/kg, 8 mg/kg, or placebo every 4 weeks with background MTX therapy.

All patients who completed the planned course of treatment or escape therapy in the WA17822 study were eligible to enter the WA18695 long-term extension study, where they were assigned to treatment with 8 mg/kg RoActemra/Actemra plus MTX. The dose of RA medications such as MTX and nonsteroidal anti-inflammatory drugs (NSAIDs), but excluding corticosteroids, was to be kept stable for the first 48 weeks of the WA18695 study. During this time dose reductions in these treatments were only allowed as clinically required for safety reasons. After week 48, the administration of disease-modifying antirheumatic drugs (DMARDs) and NSAIDs could be changed, according to the investigator's practice and as tolerated by the patient.

Being tested
Tocilizumab
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TocilizumabDrug

    Also called RoActemra, Actemra, Tocilizumab (MRA), TCZ

    Tocilizumab (myeloma receptor antibody [MRA]) was supplied in sterile solution of 20 mg TCZ/mL for aseptic preparation of infusion bags for IV administration.

Study groups in NCT00721123
Study groupRoleWhat they receive
Tocilizumab 8 mg/kgExperimentalAll participants received tocilizumab 8 mg/kg to a maximum of 800 mg, administered by intravenous (IV) infusion over one hour, every 4 weeks. Concomitant therapies were limited to dosage and administration constraints detailed in the protocol.
Receives: Drug: Tocilizumab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Adverse Event (AE) Summary Over Time

    The number of participants experiencing at least one adverse event (AE) is recorded for each 12-month time period, with multiple occurrences in a single individual counted. Because months were calculated as 28 days, the periods actually equate to 48 weeks.

    Measured: through 264 Weeks

  2. Summary Adverse Event Rates Over Time

    Patient year (PY) refers to duration in study, calculated from first active drug intake to last safety assessment available + 1. Patient year rates with confidence interval were calculated for adverse events of interest in evaluating the long-term safety of the product being studied.

    Abbreviations include the following: adverse event (AE), adverse event of special interest (AESI), gastrointestinal (GI), serious adverse event (SAE), and investigational product (IP). Hypersensitivity events were defined as AEs that occurred during or within 24 hours of IP infusion and were not deemed "unrelated" to trial treatment by the investigator. This definition includes all types of AEs, regardless of whether or not they were consistent with hypersensitivity.

    Medical confirmation of the AESI "GI perforation" was based on medical adjudication of events captured by the GI Perforation Standardised MedDRA Queries (SMQs).

    Measured: through 264 Weeks

  3. Overall Death Rate Over Time

    Patient year (PY) refers to duration in study, calculated from first active drug intake to last safety assessment available + 1.

    To calculate the death rate, the total cumulative number of years that all participants were exposed to the drug, from first active drug intake to last safety assessment available + 1, was calculated as 2461.94. Since 10 participants died during that time, the death rate per year was not informative (0.00). Therefore, the overall death rate was calculated with the confidence interval based on events per 100 patient years exposure.

    Measured: through 264 Weeks

Secondary outcomes (10)
  1. Participants Showing Improvement in Rheumatoid Arthritis Symptoms Over Time, Through 264 Weeks

    The American College of Rheumatology (ACR) established certain criteria to measure improvement in rheumatoid arthritis symptoms that include tender or swollen joint counts and five other criteria, including acute phase reactant, patient assessment, physician assessment, pain scale, and disability/functional questionnaire.

    Clinical trials use the ACR Score, based on those criteria, as a standard for reporting different degrees of improvement in rheumatoid arthritis symptoms.

    Scores on the ACR scale may be up to ACR100 because the number after "ACR" is the percent of improvement in tender or swollen joint counts as well as in three of the other five criteria. Clinical trials determine the percentage of participants who achieve that score - that percentage of improvement.

    Measured: through 264 Weeks

  2. Percentage of Participants Classified as Responders by Disease Activity Scores Over Time, Through 264 Weeks

    The disease activity score 28 (DAS28) is a combined index for measuring disease activity in rheumatic arthritis (RA) that includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The DAS28 scale ranges from 0 to 10, where lower scores represent less disease activity. Participants with DAS28 scores less than 2.6 were categorized as responders with remission and those with DAS 28 scores of 3.2 or less were categorized as responders with low disease activity (LDA). The percentage of participants classified as responders in each category was recorded over time.

    Measured: through 264 Weeks

  3. Percentage of Participants Classified as Responders by EULAR Response Over Time, Through 264 Weeks

    Participants were classified as responders based on a European League Against Rheumatism (EULAR) response of Good or Moderate. Comparing the DAS28 from one patient on two different time points, it is possible to define improvement or response. The EULAR response criteria take into consideration both the first score and the change in score in order to classify them as good response, moderate response or no response. The percentage of participants who were classified as responders was recorded, as posted below.

    Measured: through 264 Weeks

  4. Change From Baseline in Scores for Swollen and Tender Joint Counts Over Time, Through 264 Weeks

    Swollen joint count (SJC) includes an assessment of 66 joints, and tender joint count (TJC) include an assessment of 68 joints. Joint prosthesis, arthrodesis or fused joints were not considered. Joints were assessed and classified as swollen/not swollen, and tender/not tender, by pressure and joint manipulation on physical examination. Change from Baseline in the SJC and TJC were calculated at given time points, and a negative change indicates improvement.

    A small proportion of participants in the all-exposure population reduced or stopped their oral corticosteroid use due to sustained efficacy (defined as at least a 50% improvement in both swollen joint count (SJC) and tender joint count (TJC).

    Measured: through 264 Weeks

  5. Change From Baseline in Scores for Health Assessment Questionnaire - Disability Index Over Time, Through 264 Weeks

    The Stanford Health Assessment Questionnaire - Disability Index (HAQ-DI) is a questionnaire specific for rheumatoid arthritis with 8 component sets (domains): dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Each domain has 2-3 questions (for a total of 20) that participants answer with categorical answers enumerated as a scale of 0-3, where 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do.

    To calculate the HAQ-DI the patient must have a domain score for at least 6 of the eight domains. The HAQ-DI is the sum of the domain scores, divided by the number of domains that have a score (in range 6-8). The resulting HAQ-DI scores are on a scale that ranges from 0 to 3, where 0=lowest level of difficulty and 3=highest level of difficulty. A negative change from baseline indicates improvement.

    Measured: through 264 Weeks

  6. Change From Baseline in Scores for Patient's Global Assessment of Disease Activity Over Time, Through 264 Weeks

    Patient's global assessment of disease activity is the patient's overall assessment of their disease activity during specified time periods on a 100 mm horizontal visual analogue scale (VAS). The left-hand extreme of the line was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme as "maximum disease activity" (maximum arthritis disease activity). Change from baseline was calculated for given periods, and a negative change indicates improvement.

    Measured: through 264 Weeks

  7. Change From Baseline in Scores for Physician's Global Assessment of Disease Activity Over Time, Through 264 Weeks

    Physician's global assessment of disease activity is the treating physician's assessment of the patient's current disease activity on a 100 mm horizontal visual analogue scale (VAS). The extreme left end of the line was described as "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end as "maximum disease activity". Change from baseline was calculated for given periods, and a negative change indicates improvement.

    Measured: through 264 Weeks

  8. Change From Baseline in Scores for Patient's Level of Pain Over Time, Through 264 Weeks

    The patient's assessment of the patient's current level of pain on a 100 mm horizontal VAS was recorded. The extreme left end of the line was described as "no pain" and the extreme right end as "unbearable pain". Change from baseline was calculated for given periods, and a negative change indicates improvement.

    Measured: through 264 Weeks

  9. Percentage of Participants With at Least a 5-point Improvement From Baseline in Quality of Life Measure for Fatigue Over Time, Through 264 Weeks

    Quality of life is measured using the sub-scale for Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F). The assessment was originally developed for chronic illnesses and is now widely used for patients with rheumatoid arthritis.

    FACIT-F is a 13-item questionnaire. Participants score each item on a 5-point scale: 0 (Not at all) to 4 (Very much), for a highest possible score of 52. The responses are transformed into a FACIT-F score, where a higher score reflects an improvement. The percentage of participants with at least a 5-point improvement from baseline in the Facit-F score is shown at categorical time points.

    Measured: through 264 Weeks

  10. Percentage of Participants With at Least a 5-point Improvement From Baseline in Quality of Life Using the 36-Item Short-Form Health Survey (SF-36) Over Time, Through 264 Weeks

    The SF-36 Health Survey is a standardized questionnaire consisting of 36 questions that measures patient-reported symptoms on 8 dimensions; it is used to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100. A positive change score indicates better HRQoL. The percentage of participants with at least a 5-point improvement from baseline is presented for each subscale.

    Measured: through 264 Weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jul 2008 (estimated)
  2. Study startAug 2005
  3. Primary completionMay 2012
  4. Study completionMay 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
538 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00721123
Sponsor's protocol ID
WA18695
Status last verified
Nov 2013
First submitted
22 Jul 2008
Last updated
28 Nov 2013

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Tocilizumab in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 69 sites in 17 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Nov 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 69 sites in Canada, Germany, France, Israel, Mexico and 12 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 21 Oct 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Adverse Event (AE) Summary Over Time (time frame: through 264 Weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in